




RealRate

PHARMACEUTICAL 2020

Aquestive Therapeutics Inc.
Rank 255 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2020

Aquestive Therapeutics Inc.
Rank 255 of 362



The relative strengths and weaknesses of Aquestive Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aquestive Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 160% points. The greatest weakness of Aquestive Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 155% points.

The company's Economic Capital Ratio, given in the ranking table, is -338%, being 35% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	68,314
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,555
Liabilities, Non-Current	4,348
Other Assets	439
Other Compr. Net Income	0
Other Expenses	29,679
Other Liabilities	61,698
Other Net Income	-4,896
Property and Equipment	9,726
Research and Development	20,574
Revenues	53,245
Selling, General and Administrative Expense	64,342

Output Variable	Value in 1000 USD
Assets	78,479
Liabilities	84,601
Expenses	114,595
Stockholders Equity	-6,122
Net Income	-66,246
Comprehensive Net Income	-66,246
Economic Capital Ratio	-338%

